On­colyt­ic virus play­er Replimune sees progress on lead pro­gram, but fol­low-up can­di­date's ef­fec­tive­ness re­mains in­con­clu­sive

On­colyt­ic virus biotech Replimune put out a com­pre­hen­sive pipeline up­date Wednes­day morn­ing, in­di­cat­ing its lead pro­gram re­mains on its de­vel­op­ment track. But ques­tions lin­gered re­gard­ing …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER